Thermo Fisher Scientific has launched the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System for clinical laboratories and assay developers.

The launch comes after the US Food and Drug Administration (FDA) listing for the system was completed.

Introduced for in vitro diagnostic use, the qPCR platform simplifies molecular diagnostic workflows for infectious diseases, oncology and Covid-19 testing as well as helps laboratories and assay developers to meet testing demands.

The simplified, efficient workflow of the qPCR system reduces steps and provides quality results in as little as 30 minutes.

With increased sensitivity and specificity, the system provides up to six channels for multiplexing.

With simplified software, improved security and an easy-to-use interface, the cost-effective and comprehensive solution is offered in a compact footprint that can fit in any lab.

Thermo Fisher noted that clinical diagnostic and hospital laboratories in the US have ramped up PCR testing with the onset of the global Covid-19 pandemic.

These labs presently need solutions to continue Covid-19 screening as emergency use authorizations (EUAs) for SARS-CoV-2 assays are expiring.

Thermo Fisher Scientific genetic sciences president Mark Smedley said: “The Covid-19 pandemic has increased testing demands for laboratories exponentially, with a significant portion of the testing globally conducted on Thermo Fisher PCR instruments.

“As our customers’ testing requirements grow, we are continuously innovating to meet their needs with our molecular diagnostic products. With the launch of the IVD QuantStudio 5 Dx, we can continue to support our customers around the world.”

Registered in more than 50 countries, the QuantStudio 5 Dx Real-Time PCR System is listed with the FDA, CE-IVD marked under the self-certification process in the European Union and certified and approved by the National Medical Products Administration (NMPA) in China.